RxDoctor Payments Data

Alan Deutsch, DO

Neurology · Neptune, NJNPI 1528040011

Payments from drug & device makers

$16,797in general payments, 2019–2025

Across 1,202 payments — averaging $13.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • UCB, Inc.$990
  • Pfizer$858
  • Biogen$740
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$3542%
  • Food & beverage$16,41798%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis179$2,216
AbbVie(2 entities)130$1,809
Teva Pharmaceuticals USA, Inc.99$1,044
UCB, Inc.75$990
Pfizer72$858
Biogen46$740
Bristol Myers Squibb57$735
AstraZeneca54$700
EMD Serono, Inc.45$661
Lilly USA, LLC28$640
Sanofi20$499
Eisai Inc.27$348
Grifols USA, LLC19$341
Lundbeck LLC22$327
Amgen(2 entities)21$309
Biohaven Pharmaceutical Holding Company Ltd.29$297
SK Life Science, Inc.16$255
Argenx US, Inc.19$250
Johnson & Johnson18$248
Kyowa Kirin, Inc.14$197
Axsome Therapeutics, Inc.5$189
Amneal Pharmaceuticals LLC13$182
E.r. Squibb & Sons, L.L.C.13$163
Sunovion Pharmaceuticals Inc.9$158
Currax Pharmaceuticals LLC11$156
Biohaven Pharmaceuticals, Inc.15$151
Sumitomo Pharma America, Inc.10$147
CSL Behring7$134
Scilex Pharmaceuticals Inc.9$128
Acorda Therapeutics, Inc9$126
Neurocrine Biosciences, Inc.7$108
Acadia Pharmaceuticals Inc7$103
Neurelis, Inc.7$101
MDD US Operations, LLC6$100
Novocure Inc.1$97
Merz North America, Inc.5$90
Otsuka America Pharmaceutical, Inc.5$86
Upsher-smith Laboratories LLC5$84
W. L. Gore & Associates, Inc.5$79
Avanir Pharmaceuticals, Inc.5$68
Takeda Pharmaceuticals U.S.A., Inc.4$65
Adamas Pharmaceuticals, Inc.5$64
Supernus Pharmaceuticals, Inc.5$64
Life Molecular Imaging Ltd4$49
Corium, LLC3$49
Merz Pharmaceuticals, LLC3$48
Boston Scientific2$36
Medtronic(2 entities)2$35
Assertio Therapeutics, Inc.1$35
Amylyx Pharmaceuticals, Inc.2$33
Genentech USA, Inc.2$30
Avion Pharmaceuticals2$30
Impel Pharmaceuticals Inc.2$28
Cycle Pharmaceuticals Inc2$28
Xeris Pharmaceuticals, Inc.2$26
Zyla Life Sciences, Inc.2$26
Aprecia Pharmaceuticals, LLC2$24
Cala Health, Inc.1$21
Catalyst Pharmaceuticals, Inc.1$20
Nevro Corp.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,797 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$169,961
Medicare patients
603
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz13$904,102
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5034$364,170
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$169,795
FingolimodFingolimod Hcl12$86,614
AptiomEslicarbazepine Acetate19$36,030
Nurtec OdtRimegepant Sulfate20$30,512
RytaryCarbidopa/Levodopa16$29,265
NeuproRotigotine27$28,622
BriviactBrivaracetam18$26,567
XcopriCenobamate17$22,509
Depakote ErDivalproex Sodium24$12,282
Teriflunomide21$12,194
QuliptaAtogepant11$11,683
LamictalLamotrigine11$11,219
Tegretol XrCarbamazepine18$8,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$700$904,10213 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$65$364,17034 claims
Grifols USA, LLCGamunex-C$341$169,79514 claims
UCB, Inc.Neupro, Briviact$990$55,18845 claims
Sunovion Pharmaceuticals Inc.Aptiom$158$36,03019 claims
PfizerNurtec Odt, Dilantin$858$34,09237 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$182$32,54144 claims
SK Life Science, Inc.Xcopri$255$22,50917 claims
AbbVieQulipta$1,809$11,68311 claims
Upsher-smith Laboratories LLCTopiramate$84$3,20688 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.

Other neurology in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →